Revance Therapeutics Aktie
WKN DE: A1XD3D / ISIN: US7613301099
21.01.2025 14:51:27
|
Crown Laboratories, Revance Amend A&R Merger Agreement; Increases Offer Price To $3.65/shr
(RTTNews) - Crown Laboratories and Revance Therapeutics (RVNC) announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement. Revance's stockholders will receive $3.65 per share of common stock, par value $0.001 per share in cash, without interest and less any applicable tax withholding, representing $0.55 or 17% per share more than the prior offer price.
Crown will extend its existing tender offer for all of Revance's outstanding Shares until one minute past 11:59 p.m., Eastern Time, on February 4, 2025.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Revance Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |